Shenzhen Bioeasy Biotechnology Co., Ltd. (SHE:300942)
6.68
-0.09 (-1.33%)
Sep 2, 2026, 2:55 PM CST
SHE:300942 Revenue
Shenzhen Bioeasy Biotechnology had revenue of 70.72M CNY in the quarter ending June 30, 2026, with 17.98% growth. This brings the company's revenue in the last twelve months to 282.31M, up 22.80% year-over-year. In the year 2025, Shenzhen Bioeasy Biotechnology had annual revenue of 263.23M with 17.38% growth.
Revenue (ttm)
282.31M
Revenue Growth
+22.80%
P/S Ratio
9.71
Revenue / Employee
520.86K
Employees
542
Market Cap
2.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 263.23M | 38.98M | 17.38% |
| Dec 31, 2024 | 224.25M | -29.86M | -11.75% |
| Dec 31, 2023 | 254.11M | -432.79M | -63.01% |
| Jan 1, 2023 | 686.90M | 89.36M | 14.95% |
| Jan 1, 2022 | 597.54M | 339.08M | 131.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Beijing Kawin Technology Share-Holding | 1.23B |
| Shanghai Universal Biotech | 1.15B |
| Shandong Sito Bio-technology | 1.12B |
| Zhejiang East Asia Pharmaceutical | 990.47M |
| Guangdong VTR Bio-Tech | 814.07M |
| Landfar Bio-medicine | 660.26M |
| Hubei Goto Biopharm Group | 650.05M |
| Zhejiang Shouxiangu Pharmaceutical | 611.43M |